ArticleCancer discovery2021
Enhancer Hijacking Drives Oncogenic
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers.
0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed
16.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
119 citing papers in PubMed, 181 citations in OpenAlex.
- Trial
- ETV6 Rearrangement Suppresses CDKN1B Transcription by Disrupting an Intragenic Super-enhancer in Acute Lymphoblastic Leukemia.Cancer research · 2026Article
- Single-cell epigenomics of colorectal cancer.Experimental & molecular medicine · 2026Review
- Plasticity under pressure: biology and detection of lineage switch in acute leukemia.Leukemia · 2026Review
- A genomic and epigenomic lens into the biology of acute lymphoblastic leukaemia.Nature reviews. Cancer · 2026Review
- Integrative Transcriptional and Chromatin Analyses Reveal Enhancer-Mediated Regulatory Programs Driving Breast Cancer Metastasis.Molecular cancer research : MCR · 2026Article
- Article
- Significance of Myelodysplasia-Related Mutations and the Genetic Landscape of Acute Leukemias of Ambiguous Lineage.International journal of laboratory hematology · 2026Review
- Hi-C for genome-wide detection of enhancer-hijacking rearrangements in routine lymphoid cancer biopsies.Cell genomics · 2026Article
- The landscape of structural variation in pediatric cancer.Cancer cell · 2026Article
- Bipartite DNA binding domain of transcription factor BCL11B binds clustered short DNA sequence motifs.bioRxiv : the preprint server for biology · 2026Article
- BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Exploiting tumor lineage features for precision cancer therapy.Trends in cancer · 2026Review
- Histo-LCM-Hi-C Reveals 3D Chromatin Conformations of Spatially Localized Rare Cells in Tissues at High Resolution.Genomics, proteomics & bioinformatics · 2026Article
- Streptomyces koyangensis L-asparaginase: computational prediction of dual-mechanism BCL-2 interaction in acute lymphoblastic leukemia.Scientific reports · 2026Article
- Acute leukemia of ambiguous lineage: the known and the uncertain.Haematologica · 2026Review
- Optical genome mapping reveals a recurrent translocation, t(14;16), in T/myeloid mixed phenotype acute leukemia: report of two cases.Molecular cytogenetics · 2026Article
- Article
- Mechanisms of enhancer-driven oncogene activation.International journal of cancer · 2026Review
- FOXP3 expression depends on cell-type-specific cis-regulatory elements and transcription factor circuitry.Immunity · 2026Article
59 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
52 authors at 16 institutions in 5 countries.
Lindsey E Montefiori *Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Sonja Bendig *Munich Leukemia Laboratory, Munich, Germany.
Zhaohui Gu *Department of Computational and Quantitative Medicine, City of Hope Comprehensive Cancer Center, Duarte, California.ORCID 0000-0003-1581-1327
Xiaolong Chen *Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0001-8283-0582
Petri PölönenDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Xiaotu MaDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-6233-2145
Alex MurisonDepartment of Molecular Genetics, University of Toronto, Toronto, Canada.
Andy ZengDepartment of Molecular Genetics, University of Toronto, Toronto, Canada.
Laura Garcia-PratDepartment of Molecular Genetics, University of Toronto, Toronto, Canada.
Kirsten DickersonDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Ilaria IacobucciDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Sherif AbdelhamedDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-3319-2403
Ryan HiltenbrandDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Paul E MeadDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Cyrus M MehrDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Beisi XuCenter for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0003-0099-858X
Zhongshan ChengCenter for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, Tennessee.
Ti-Cheng ChangCenter for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, Tennessee.
Tamara WestoverDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Jing MaDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Anna StengelMunich Leukemia Laboratory, Munich, Germany.
Shunsuke KimuraDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-2158-467X
Chunxu QuDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Marcus B ValentineCytogenetics Core Facility, St. Jude Children's Research Hospital, Memphis, Tennessee.
Marissa RashkovanInstitute for Cancer Genetics, Columbia University, New York, New York.ORCID 0000-0002-6990-8186
Selina LugerAbramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
Mark R LitzowDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Jacob M RoweDepartment of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.
Monique L den BoerPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.ORCID 0000-0002-5795-2921
Victoria WangDepartment of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Jun YinDivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0003-3242-9664
Steven M KornblauDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Stephen P HungerDepartment of Pediatrics, Children's Hospital of Philadelphia, and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0002-5492-3957
Mignon L LohDepartment of Pediatrics, Benioff Children's Hospital and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
Ching-Hon PuiDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0003-0303-5658
Wenjian YangDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-7305-5649
Kristine R CrewsDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-7558-558X
Kathryn G RobertsDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0001-7626-4043
Jun J YangDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.
Mary V RellingDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.
William E EvansDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.
Wendy StockUniversity of Chicago Comprehensive Cancer Center, Chicago, Illinois.ORCID 0000-0002-8349-9200
Elisabeth M PaiettaDepartment of Oncology, Montefiore Medical Center, Bronx, New York.
Adolfo A FerrandoInstitute for Cancer Genetics, Columbia University, New York, New York.
Jinghui ZhangDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0003-3350-9682
Wolfgang KernMunich Leukemia Laboratory, Munich, Germany.
Torsten HaferlachMunich Leukemia Laboratory, Munich, Germany.
Gang WuDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
John E DickDepartment of Molecular Genetics, University of Toronto, Toronto, Canada.ORCID 0000-0002-9527-8317
Jeffery M KlcoDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee. charles.mullighan@stjude.org Jeffery.klco@stjude.org Claudia.haferlach@mll.com.ORCID 0000-0003-2961-6960
Claudia HaferlachMunich Leukemia Laboratory, Munich, Germany. charles.mullighan@stjude.org Jeffery.klco@stjude.org Claudia.haferlach@mll.com.
Charles G MullighanDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee. charles.mullighan@stjude.org Jeffery.klco@stjude.org Claudia.haferlach@mll.com.ORCID 0000-0002-1871-1850
St. Jude Children's Research Hospital · USMunich Leukemia Laboratory (Germany) · DEUniversity of Toronto · CAMayo Clinic · USCancer Genetics (United States) · USChildren's Hospital of Philadelphia · USCity of Hope · USColumbia University Irving Medical Center · USDana-Farber Cancer Institute · USMontefiore Medical Center · USPrincess Máxima Center · NLShaare Zedek Medical Center · ILThe University of Texas MD Anderson Cancer Center · USUCSF Helen Diller Family Comprehensive Cancer Center · USUniversity of Chicago · USUniversity of Pennsylvania · US
Funding
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3MProject-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6MViral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Gregory Armstrong · 1985 to 2026
$166.9MStatistics CoreU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO, CONSTANTINE A. GATSONIS · 2014 to 2026
$111.2MECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · 2015 to 2026
$41.1MTHE ALLIANCE NCTN BIOREPOSITORY AND BIOSPECIMEN RESOURCEU24CA196171 · NCI · WASHINGTON UNIVERSITY · PI Mine Cicek, Wendy Frankel · 2015 to 2026
$35.0MCPML - Project 3: Genome-wide Studies of Adverse EffectsP50GM115279 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI LOH, MIGNON LEE-CHEUN, RELLING, MARY V · 2015 to 2019
$15.1MTranslating genomic discoveries to improved outcomes for high risk acute leukemiaR35CA197695 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Charles G Mullighan · 2017 to 2026
$11.4MCase Comprehensive Cancer Center NCTN Lead Academic Participating SiteUG1CA233234 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Aaron Thomas Gerds, Daniel Eidelberg Spratt · 2019 to 2026
$11.1MMontefiore Academic Community NCORP ProgramUG1CA189859 · NCI · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI Balazs Halmos, Della Makower · 2014 to 2026
$10.8MNetwork Lead Academic Participating Site: Memorial Sloan Kettering Cancer CenterUG1CA233290 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CAROL AGHAJANIAN, Darren Feldman · 2019 to 2026
$10.2MNCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1 (funded extension)UG1CA232760 · NCI · MAYO CLINIC ROCHESTER · PI Judy Caroline Boughey, Aaron Scott Mansfield · 2019 to 2026
$8.5MCIHR RN380110-409786NCI NIH HHS F32 CA254140NCI NIH HHS K99 CA279756NCI NIH HHS P30 CA021765NCI NIH HHS R00 CA241297NCI NIH HHS R01 CA216391NCI NIH HHS R35 CA197695NCI NIH HHS R35 CA210065NCI NIH HHS RC1 CA145707NCI NIH HHS T32 CA236748NCI NIH HHS U10 CA180794NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180821NCI NIH HHS U24 CA196171NCI NIH HHS U24 CA196172NCI NIH HHS UG1 CA189859NCI NIH HHS UG1 CA232760NCI NIH HHS UG1 CA233234NCI NIH HHS UG1 CA233290NIGMS NIH HHS P50 GM115279
Abstract
Lineage-ambiguous leukemias are high-risk malignancies of poorly understood genetic basis. Here, we describe a distinct subgroup of acute leukemia with expression of myeloid, T lymphoid, and stem cell markers driven by aberrant allele-specific deregulation of
Indexed as
Enhancer Elements, GeneticLeukemia, Myeloid, AcuteRepressor ProteinsTumor Suppressor ProteinsGene Regulatory NetworksHematopoietic Stem CellsHumansTranscription FactorsBCL11B protein, humanRepressor ProteinsTranscription FactorsTumor Suppressor Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.